[HTML][HTML] 2022 年度胰腺癌研究及诊疗新进展
王旭， 程合， 刘辰， 虞先濬 - 中国癌症杂志, 2023 - china-oncology.com
胰腺癌是中国致死人数排名第六的恶性肿瘤, 其恶性程度高, 早期病情隐匿, 超过80%
的患者在就诊时已进展为晚期, 错失手术切除治愈的机会; 而成功接受了手术治疗的胰腺癌患者 …
的患者在就诊时已进展为晚期, 错失手术切除治愈的机会; 而成功接受了手术治疗的胰腺癌患者 …
Contemporary approaches to the diagnosis and management of Pancreatic Ductal adenocarcinoma, examining the role of biomarkers in aiding early diagnosis
M MORTIMER - 2024 - cronfa.swan.ac.uk
Whilst other cancers have seen improvements in survival over recent decades, Pancreatic
Ductal Adenocarcinoma (PDAC) remains a disease with poor outcomes. At present no …
Ductal Adenocarcinoma (PDAC) remains a disease with poor outcomes. At present no …
New progress in basic research, clinical diagnosis and treatment of pancreatic cancer in 2022
W Xu, C He, LIU Chen, YU Xianjun - China Oncology, 2023 - china-oncology.com
Pancreatic cancer is the sixth leading cause of cancer-related death in China. It is
characterized by high malignancy and concealment at early stages. More than 80% of …
characterized by high malignancy and concealment at early stages. More than 80% of …